Key Developments: Abiomed Inc (ABMD.OQ)
24.15USD
1 Aug 2013
$-0.93 (-3.71%)
$25.08
$25.22
$25.22
$22.94
422,319
118,161
$25.24
$11.82
Latest Key Developments (Source: Significant Developments)
Abiomed Inc Reaffirms FY 2013 Revenue Guidance
Abiomed Inc maintained its fiscal 2014 revenue guidance in a range of $180 million to $185 million. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $184 million for fiscal 2014. Full Article
Abiomed Inc Issues FY 2014 Revenue Guidance In Line With Analysts' Estimates
Abiomed Inc announced that for fiscal 2014, it expects revenue to be in the range of $180 million to $185 million.According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $181 million for fiscal 2014. Full Article
Abiomed Inc Reaffirms FY 2013 Revenue Guidance
Abiomed Inc announced that it is maintaining its fiscal 2013 revenue guidance in a range of $155 million to $157 million, representing annual growth of 23% to 24%, with worldwide Impella revenues forecast to grow greater than 30%. According to I/B/E/S Estimates, analysts on an average are expecting the Company to report revenue of $156 million for fiscal 2013. Full Article
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Abiomed Inc
Glancy Binkow & Goldberg LLP announced that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of all purchasers of the securities of Abiomed Inc ("Abiomed" or the "Company") between August 5, 2011 and October 31, 2012, inclusive (the "Class Period"). Investors who have losses of $100,000 or more are encouraged to contact the firm for information concerning a lead plaintiff position in the class action suit. Full Article
Levi & Korsinsky Notifies Investors With Losses on Their Investment in Abiomed Inc of Class Action Lawsuit and Deadline of January 15, 2013 to Seek Lead Plaintiff Position
Levi & Korsinsky announced that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who purchased Abiomed Inc. The complaint alleges that, throughout the Class Period, Abiomed made materially misleading statements regarding the Company's financial strength and prospects. In particular, it is alleged that positive statements concerning the Company were misleading because the United States Food and Drug Administration (FDA) repeatedly warned Abiomed that its promotional materials contained inappropriate claims regarding its Impella 2.5 catheter and suggested improper off-label uses. Abiomed repeatedly assured investors that they had addressed the FDA's concerns and that the matter was resolved. Full Article
The Shareholders Foundation, Inc. Announces Lawsuit Against Abiomed Inc
The Shareholders Foundation, Inc. announced that a lawsuit was filed on behalf of purchasers of Abiomed Inc (ABMD) common stock during the period between February 15, 2012 and November 6, 2012. Full Article
Law Offices of Todd M. Garber Announces Lead Plaintiff Deadline In Class Action Lawsuit Against Abiomed Inc
The Law Offices of Todd M. Garber announced that shareholders of Abiomed Inc have until January 15, 2013 to move for lead plaintiff status in the shareholder lawsuit filed in the United States District Court for the District of Massachusetts. The lawsuit was filed on behalf of a class (the Class) comprising all purchasers of Abiomed securities between August 5, 2011 and October 31, 2012, inclusive (the Class Period). The Complaint alleges that throughout the Class Period the defendants made materially false and misleading statements regarding the Company's business, operations and financial prospects. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company was improperly marketing and/or labeling its Impella 2.5 system; (2) Abiomed's financial results would be materially impacted if the Company were either forced to stop or discontinued its improper conduct; (3) the Company lacked adequate internal and financial controls; and (4) as a result of the foregoing, the Company's statements were materially false and misleading at all relevant times. Full Article
Law Offices of Todd M. Garber Announces Class Action Lawsuit Against Abiomed Inc
The Law Offices of Todd M. Garber announced that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of a class comprising all persons or entities who purchased the securities of Abiomed Inc between August 5, 2011 and October 31, 2012, inclusive (the Class Period). Abiomed is a provider of medical devices for circulatory support and offers a continuum of care in heart recovery for acute heart failure patients. The Company`s Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors, designed primarily for use by interventional cardiologists to support patients in the cardiac catheterization lab who may require assistance to maintain their circulation. The Complaint alleges that throughout the Class Period the defendants made materially false and misleading statements regarding the Company`s business, operations and financial prospects. Specifically, defendants misrepresented and/or failed to disclose that: (1) the Company was improperly marketing and/or labeling its Impella 2.5 system; (2) Abiomed`s financial results would be materially impacted if the Company were either forced to stop or discontinued its improper conduct; (3) the Company lacked adequate internal and financial controls; and (4) as a result of the foregoing, the Company`s statements were materially false and misleading at all relevant times. Full Article
The Shuman Law Firm Announces Filing Of Securities Class Action Lawsuit Against Abiomed Inc
The Shuman Law Firm announced that a lawsuit seeking class action status has been filed in the U.S. District Court for the District of Massachusetts on behalf of purchasers of Abiomed, Inc (Abiomed or the Company) securities between August 5, 2011 and October 31, 2012, inclusive (the Class Period). On November 1, 2012, prior to the opening of the markets, Abiomed disclosed that the United States Attorney's Office for the District of Columbia was conducting an investigation into Abiomed's marketing and labeling of its Impella 2.5 system. As a result of this news, shares of Abiomed declined $6.31 per share, or 31.33%, to close on November 1, 2012 at $13.61, on heavy trading volume. Full Article
Todd M. Garber Announces Investigation Of Abiomed Inc
Todd M. Garber announced that it is investigating potential claims against Abiomed, Inc. ("Abiomed" or the "Company") concerning possible violations of federal securities laws. The investigation is related to allegations that certain statements issued by Abiomed between August 5, 2011 and October 31, 2012 were false and misleading concerning the Company`s business, operations and financial prospects. The investigation is related to allegations that the Company misrepresented and/or failed to disclose that: Abiomed was improperly marketing and/or labeling its Impella 2.5 system; Abiomed`s financial results would be materially impacted if the Company were either forced to stop or discontinued its improper conduct; the Company lacked adequate internal and financial controls; and as a result of the foregoing, the Company`s statements were materially false and misleading at all relevant times. Full Article
BRIEF-Abiomed shares up 7.2 pct, volume high
NEW YORK, April 17 - Abiomed Inc : * Shares up 7.2 percent, volume above 25-day average

Earnings vs.
Estimates